Investor Presentation First Nine Months of 2023
59
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Large opportunity for activating more people with obesity to
seek treatment and increasing the number of prescribers
ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg
77%
WegovyⓇ patient characteristics in the US
30%
81%
37.5
of patients new to anti-
obesity medication¹
of patients are female
Average BMI
of patients have ≥3 co-
morbidities
Of the people with overweight or obesity in the US, almost 90% have a weight-related comorbidity
BMI
(million of people)
27-30
(43)
30-35
(52)
35-40
(25)
≥40
(20)
140
No obesity-related comorbidity²
7 (16%)
6 (12%)
2 (9%)
2 (8%)
Total
(140)
17 (12%)
million people with a
BMI > 27
Any obesity-related comorbidity
Hereof metabolic syndrome³
36 (84%)
46 (88%)
23 (92%)
18 (90%)
123 (88%)
21 (48%)
26 (50%)
14 (56%)
12 (61%)
72 (52%)
Hereof ASCVD
4 (8%)
5 (10%)
3 (10%)
2 (10%)
13 (9%)
¹Naïve to AOM treatment is based on total info in the database and not restricted to 12 months prior WegovyⓇ prescription 2 Individuals without any of the following obesity related conditions: T2DM, Pre-diabetes, MASH, MAFLD, obstructive sleep apnea,
osteoarthritis, PCOS, ASCVD, Heart failure, asthma, urinary incontinence, hypertension, chronic kidney disease stg. 3 or 4, musculoskeletal pain, dyslipideamia, metabolic syndrome; 3 Metabolic syndrome defined as two or more of dyslipidaemia; hypertension;
prediabetes OR type II diabetes
Source: Novo Nordisk real world research; National Health And Examination Survey (NHANES) cycles 2015-2016 and 2017-2018. BMI; Body mass index; ASCVD: Atherosclerotic cardiovascular diseaseView entire presentation